UNICHEM LABORATORIES
|
UNICHEM LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -28.72 | 4.70 | 4.88 | -8.55 | -3.38 |
| CEPS(Rs) | -12.61 | 17.64 | 16.91 | 2.94 | 6.18 |
| DPS(Rs) | - | 4.00 | 4.00 | 4.00 | 4.00 |
| Book NAV/Share(Rs) | 344.18 | 370.39 | 362.05 | 358.85 | 371.69 |
| Tax Rate(%) | -14.67 | -50.49 | 33.10 | -24.42 | 58.50 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | -3.39 | 5.73 | 7.38 | -4.60 | -6.82 |
| EBIT Margin(%) | -11.84 | 2.21 | 4.61 | -3.73 | -4.21 |
| Pre Tax Margin(%) | -13.13 | 1.73 | 4.20 | -4.44 | -4.84 |
| PAT Margin (%) | -15.06 | 2.60 | 2.81 | -5.53 | -2.01 |
| Cash Profit Margin (%) | -6.61 | 9.78 | 9.64 | 1.87 | 3.66 |
| Performance Ratios | |||||
| ROA(%) | -6.22 | 1.03 | 1.11 | -1.94 | -0.75 |
| ROE(%) | -8.04 | 1.28 | 1.37 | -2.37 | -0.90 |
| ROCE(%) | -5.60 | 1.00 | 2.12 | -1.49 | -1.77 |
| Asset Turnover(x) | 0.41 | 0.40 | 0.40 | 0.35 | 0.38 |
| Sales/Fixed Asset(x) | 0.86 | 0.99 | 1.08 | 1.06 | 1.43 |
| Working Capital/Sales(x) | 1.42 | 1.16 | 1.42 | 0.99 | 0.77 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.17 | 1.01 | 0.93 | 0.94 | 0.70 |
| Receivable days | 147.31 | 107.17 | 94.63 | 136.61 | 109.51 |
| Inventory Days | 166.52 | 163.63 | 138.14 | 121.57 | 93.93 |
| Payable days | 179.25 | 201.09 | 278.03 | 278.88 | 224.32 |
| Valuation Parameters | |||||
| PER(x) | - | 55.44 | 63.44 | - | - |
| PCE(x) | -22.92 | 14.76 | 18.30 | 51.54 | 31.49 |
| Price/Book(x) | 0.84 | 0.70 | 0.85 | 0.42 | 0.52 |
| Yield(%) | - | 1.54 | 1.29 | 2.64 | 2.06 |
| EV/Net Sales(x) | 1.60 | 1.61 | 1.78 | 0.92 | 1.15 |
| EV/Core EBITDA(x) | -304.97 | 17.03 | 15.54 | 25.09 | 78.69 |
| EV/EBIT(x) | -13.50 | 73.00 | 38.56 | -24.67 | -27.38 |
| EV/CE(x) | 0.67 | 0.62 | 0.71 | 0.32 | 0.44 |
| M Cap / Sales | 1.52 | 1.44 | 1.76 | 0.97 | 1.15 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 5.76 | 2.81 | 11.91 | -7.11 | -13.89 |
| Core EBITDA Growth(%) | -105.85 | -14.86 | 248.94 | 132.88 | -99.47 |
| EBIT Growth(%) | -666.54 | -50.70 | 238.29 | 17.61 | -101.54 |
| PAT Growth(%) | -711.67 | -4.63 | 156.84 | -155.58 | -100.94 |
| EPS Growth(%) | -711.66 | -3.68 | 157.03 | -152.78 | -100.93 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.12 | 0.13 | 0.04 | 0.07 | 0.08 |
| Current Ratio(x) | 2.48 | 2.98 | 2.72 | 2.98 | 4.05 |
| Quick Ratio(x) | 1.51 | 1.89 | 1.66 | 2.28 | 3.38 |
| Interest Cover(x) | -9.19 | 4.60 | 11.12 | -5.25 | -6.64 |
| Total Debt/Mcap(x) | 0.15 | 0.18 | 0.05 | 0.17 | 0.15 |
Compare Financial Ratios of peers of UNICHEM LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| UNICHEM LABORATORIES | ₹4,083.2 Cr | 0.4% | 15.1% | 56.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹364,831.0 Cr | -0.1% | -2.8% | 50.3% | Stock Analytics | |
| CIPLA | ₹113,471.0 Cr | 4.5% | -3.1% | 52.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,713.0 Cr | 4.6% | 1.4% | 22.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹101,960.0 Cr | 4.7% | 10.8% | 18.1% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,687.8 Cr | 3.1% | -4.1% | 80.4% | Stock Analytics | |
UNICHEM LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| UNICHEM LABORATORIES | 0.4% |
15.1% |
56.5% |
| SENSEX | 1.3% |
2.6% |
24% |
You may also like the below Video Courses
